3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional,
multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of
complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis®
(1mg/mL ciclosporin) eye drops administered once daily